OrthoPediatrics announces successful U.S. surgeries using the VerteGlide system to treat Early Onset Scoliosis.
Quiver AI Summary
OrthoPediatrics Corp. has successfully completed the first surgical procedures in the U.S. using its VerteGlide Spinal Growth Guidance System to treat Early Onset Scoliosis (EOS). Dr. Richard McCarthy, a pediatric orthopedic surgeon, praised the innovation as a significant advancement in addressing a critical unmet need for EOS patients, who have limited treatment options. The VerteGlide system, part of OrthoPediatrics' Scoliosis product suite, incorporates advanced technology to assist surgeons in correcting complex spinal deformities. The system will be showcased at upcoming medical conferences, and is made possible by a licensing agreement with Medtronic for Shilla™ technology. Founded in 2006, OrthoPediatrics is dedicated to improving pediatric orthopedic care and currently offers over 80 products globally.
Potential Positives
- Completion of first U.S. surgical procedures with the VerteGlide Spinal Growth Guidance System, marking a significant advancement in the treatment of Early Onset Scoliosis.
- Positive feedback from leading pediatric orthopedic surgeons, highlighting the breakthrough nature of the technology and its potential to meet a significant unmet clinical need.
- The VerteGlide system will be featured at prominent medical conferences, enhancing visibility and credibility within the orthopedic community.
- OrthoPediatrics’ commitment to pediatric orthopedics is reinforced with the launch of this advanced system, further solidifying its position in the market.
Potential Negatives
- While the release highlights the successful use of the VerteGlide system, it does not provide specific data or outcomes from the initial procedures, potentially raising concerns about the effectiveness and safety of the new technology.
- The reliance on licensed technology from Medtronic (Shilla™), while beneficial, may indicate a lack of proprietary advancements within OrthoPediatrics, which could affect long-term competitive positioning in the market.
- There is no mention of regulatory approvals or market readiness, which could imply potential delays or challenges in wider adoption of the VerteGlide system.
FAQ
What is the VerteGlide Spinal Growth Guidance System?
The VerteGlide is a system designed to treat Early Onset Scoliosis using advanced implant and instrument technology.
Who performed the first surgeries with VerteGlide?
Dr. Richard McCarthy and Dr. Kent Walker conducted the first surgical procedures using the VerteGlide system.
What clinical need does VerteGlide address?
VerteGlide addresses a significant unmet clinical need for children with Early Onset Scoliosis, offering a new treatment option.
When will VerteGlide be featured at medical conferences?
VerteGlide will be showcased at the Scoliosis Research Society's 60th Annual Meeting in September and the International Congress in November.
What is the mission of OrthoPediatrics Corp.?
OrthoPediatrics is dedicated to advancing pediatric orthopedics by developing innovative products to improve children's lives with orthopedic conditions.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$KIDS Insider Trading Activity
$KIDS insiders have traded $KIDS stock on the open market 6 times in the past 6 months. Of those trades, 1 have been purchases and 5 have been sales.
Here’s a breakdown of recent trading of $KIDS stock by insiders over the last 6 months:
- FRED HITE (COO and CFO) has made 1 purchase buying 5,076 shares for an estimated $98,525 and 1 sale selling 6,443 shares for an estimated $160,172.
- DAVID R BAILEY (President and CEO) sold 6,620 shares for an estimated $164,573
- GREGORY A ODLE (President of Scoliosis) sold 5,359 shares for an estimated $133,224
- DANIEL J GERRITZEN (General Counsel and Secretary) sold 5,310 shares for an estimated $132,006
- JOSEPH W HAUSER (Pres. Trauma & Def. Correction) sold 5,300 shares for an estimated $131,758
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$KIDS Hedge Fund Activity
We have seen 49 institutional investors add shares of $KIDS stock to their portfolio, and 65 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- WASATCH ADVISORS LP removed 402,223 shares (-56.0%) from their portfolio in Q2 2025, for an estimated $8,639,750
- GRANAHAN INVESTMENT MANAGEMENT, LLC added 299,771 shares (+44.9%) to their portfolio in Q2 2025, for an estimated $6,439,081
- HARBOR CAPITAL ADVISORS, INC. added 179,733 shares (+116.5%) to their portfolio in Q2 2025, for an estimated $3,860,664
- MORGAN STANLEY added 169,622 shares (+16.1%) to their portfolio in Q2 2025, for an estimated $3,643,480
- GOLDMAN SACHS GROUP INC removed 132,735 shares (-66.2%) from their portfolio in Q2 2025, for an estimated $2,851,147
- MILLENNIUM MANAGEMENT LLC added 124,449 shares (+19.0%) to their portfolio in Q2 2025, for an estimated $2,673,164
- BROWN CAPITAL MANAGEMENT LLC removed 113,821 shares (-6.8%) from their portfolio in Q2 2025, for an estimated $2,444,875
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$KIDS Analyst Ratings
Wall Street analysts have issued reports on $KIDS in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- JMP Securities issued a "Market Outperform" rating on 08/08/2025
- Piper Sandler issued a "Overweight" rating on 05/08/2025
- Needham issued a "Buy" rating on 05/08/2025
- Lake Street issued a "Buy" rating on 04/07/2025
- Citizens Capital Markets issued a "Market Outperform" rating on 03/21/2025
To track analyst ratings and price targets for $KIDS, check out Quiver Quantitative's $KIDS forecast page.
$KIDS Price Targets
Multiple analysts have issued price targets for $KIDS recently. We have seen 7 analysts offer price targets for $KIDS in the last 6 months, with a median target of $37.0.
Here are some recent targets:
- David Turkaly from JMP Securities set a target price of $35.0 on 08/08/2025
- Ryan Zimmerman from BTIG set a target price of $39.0 on 08/06/2025
- Matt O'Brien from Piper Sandler set a target price of $30.0 on 05/08/2025
- Mike Matson from Needham set a target price of $42.0 on 05/08/2025
- Richard Newitter from Truist Securities set a target price of $24.0 on 04/11/2025
- Ben Haynor from Lake Street set a target price of $37.0 on 04/07/2025
- David Turkaly from Citizens Capital Markets set a target price of $50.0 on 03/21/2025
Full Release
WARSAW, Ind., Sept. 10, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the completion of the first U.S. surgical procedures with the VerteGlide Spinal Growth Guidance System (“VerteGlide”), used to treat Early Onset Scoliosis (“EOS”).
Dr. Richard McCarthy, a pediatric orthopedic spine surgeon in Louisville, Kentucky who, along with Dr. Kent Walker, performed one of the first procedures shared, “The first procedures with VerteGlide were a great success. For these patients, there is a very limited set of options, and this breakthrough growth guidance system offers a solution for a significant unmet clinical need. This technology will greatly benefit the first patients and many other kids in the future. OrthoPediatrics should feel very proud of the work put into creating this device for the benefit of children”.
As part of OrthoPediatrics’ Scoliosis suite of products, VerteGlide provides another unique alternative for the treatment of scoliosis that leverages advanced implant and instrument technology. VerteGlide is a unique Scoliosis deformity correction system for early onset scoliosis patients that exhibit some of the most complex spinal pathology. In addition, VerteGlide will be featured at the upcoming 60th Annual Meeting of the Scoliosis Research Society in September, and the 19th International Congress on Early Onset Scoliosis meeting in November.
OrthoPediatrics Scoliosis division President, Greg Odle commented, “By leveraging the knowledge of a first-class surgeon design team that has the most practical knowledge of pediatric spinal growth guidance concepts, this system offers surgeons a unique ability to treat EOS by addressing the most diseased areas of the spinal column. The complex nature of EOS demands that surgeons have access to the most cutting-edge technology available. We are pleased to offer the most advanced system on the market and to see the success of the first procedures.”
The VerteGlide Spinal Growth Guidance System is made possible with the Shilla ™ technology licensed from Medtronic.
About OrthoPediatrics Corp.
Founded in 2006, OrthoPediatrics is an orthopedic company focused exclusively on advancing the field of pediatric orthopedics. As such, it has developed the most comprehensive product offering to the pediatric orthopedic market to improve the lives of children with orthopedic conditions. OrthoPediatrics currently markets over 80 products that serve three of the largest categories within the pediatric orthopedic market. This product offering spans trauma and deformity, scoliosis, and sports medicine/other procedures. OrthoPediatrics’ global sales organization is focused exclusively on pediatric orthopedics and distributes its products in the United States and over 70 countries outside the United States. For more information, please visit www.orthopediatrics.com . For more information about the OrthoPediatrics Specialty Bracing portfolio, please visit www.opsb.com .
Investor Contact
Philip Trip Taylor
Gilmartin Group
[email protected]
415-937- 5406
